OncoMatch/Pancreatic Cancer (PDAC)/BRCA1
Pancreatic Cancer (PDAC)BRCA1 Clinical Trials
Germline BRCA1 pathogenic variants occur in approximately 1–3% of pancreatic ductal adenocarcinoma (PDAC) and confer sensitivity to platinum-based chemotherapy and PARP inhibition through homologous recombination deficiency. Olaparib maintenance after platinum-based induction is FDA-approved for germline BRCA1/2-positive metastatic PDAC. Trials explore PARP inhibitor combinations with ATR/CHK1 inhibitors and immunotherapy, and somatic BRCA1 alteration eligibility.
Top recruiting BRCA1 Pancreatic Cancer (PDAC) trials
Ranked by phase and US site count.
See all trials matched to your profile →The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
AstraZeneca
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco